KLARICID® 500 mg επικαλυμμένα με λεπτό υμένιο δισκία
Sponsors
Hellenic Institute For The Study Of Sepsis, Elliniko Institouto Meletis Tis Sipsis, Verisfield Single Member S.A.
Conditions
Community- acquired pneumonia related sepsis with evidence of Sepsis Induced Immunoparalysis SIICommunity-acquired pneumoniaHelicobacter Pylori Infection
Phase 3
Biomarker-Guided Early Clarithromycin Treatment To Prevent Sepsis Progression In Community-Acquired Pneumonia: The REACT Randomized Clinical Trial
RecruitingCTIS2023-507295-40-00
Start: 2024-02-12Target: 330Updated: 2025-11-03
A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.
Not yet recruitingCTIS2026-525291-26-00
Target: 420Updated: 2026-05-28
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
Not yet recruitingCTIS2025-525058-20-00
Target: 252Updated: 2026-06-29